First meeting of the EChiLiBRiST consortium

All partners of EChiLiBRiST consortium met February 8-10 in Barcelona for the kick-off meeting of the project. The consortium, led by ISGlobal – Institut de Salut Global de Barcelona, is formed by 13 research institutions from Europe, Africa and North America. The main goal of the project is to develop and clinically validate a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and thus, enhance child survival.

BioEclosion S.L. has a key role in the consortium, as presented by CEO Dr. Jofre Ferrer-Dalmau in the meeting. The development and validation of BioEclosion’s MagnetPlex point-of-care platform (based on the disposable cartridge patented by BioEclosion) is central for the project. The MagnetPlex platform will be used to obtain quantitative and fast measurements of two biomarkers that can predict the severity of febrile patients, enabling the clinicians to take almost immediate clinical decisions.

The test will be developed and produced by BioEclosion, UAB – Universitat Autònoma de Barcelona – Biosensing and Bioanalysis Group, and Eurecat.

For more information, please check the project website.

Kick-off meeting of AmpliSens project, led by BioEclosion

The AmpliSens Consortium met for the kick-off of the project past 15th of December 2022. The Consortium is led by BioEclosion, partnering with ‘Universitat Autònoma de Barcelona’ (Research group led by Prof. Isabel Pividori), ISGlobal (Research group led by Prof. Quique Bassat) and EureCat technology center. Dr. Jofre Ferrer-Dalmau, CEO from BioEclosion S.L., will coordinate this project, granted under the call for ‘Proyectos de colaboración público-privada 2021’ from Spanish Ministry of Science and Innovation, and funded from European Union – Next Generation EU/PRTR (Sept 2022 – Aug 2025).

The aim of the project is to develop a rapid and portable molecular test for the screen-out of neonatal sepsis due to Group B streptococcus (GBS) of the suspected newborn and for the screening of pregnant women. The proposed test can be used both in low resource settings where microbiological cultures are not available, and in high income countries to dramatically improve turnaround times for results and reduce costs.

For more information, check the project website.